<?xml version="1.0" encoding="UTF-8"?><OAI-PMH
	xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2019-03-02T19:31:04Z</responseDate><request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:2212104" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request><GetRecord><record><header><identifier>oai:pubmedcentral.nih.gov:2212104</identifier><datestamp>2008-04-16</datestamp><setSpec>jexpmed</setSpec><setSpec>pmc-open</setSpec></header><metadata><article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.0/ https://jats.nlm.nih.gov/archiving/1.0/xsd/JATS-archivearticle1.xsd" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Exp Med</journal-id>
      <journal-id journal-id-type="iso-abbrev">J. Exp. Med</journal-id>
      <journal-title-group>
        <journal-title>The Journal of Experimental Medicine</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0022-1007</issn>
      <issn pub-type="epub">1540-9538</issn>
      <publisher>
        <publisher-name>The Rockefeller University Press</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="accession">PMC2212104</article-id>
      <article-id pub-id-type="pmcid">PMC2212104</article-id>
      <article-id pub-id-type="pmc-uid">2212104</article-id>
      <article-id pub-id-type="pmid">9432981</article-id>
      <article-id pub-id-type="pmid">9432981</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Article</subject>
          <subj-group>
            <subject>Articles</subject>
          </subj-group>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Tumor Necrosis Factor Receptorâassociated Factor 6 (TRAF6) Stimulates Extracellular Signalâregulated Kinase (ERK) Activity in CD40 Signaling Along a Ras-independent Pathway </article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Kashiwada</surname>
            <given-names>Masaki</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Shirakata</surname>
            <given-names>Yumiko</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Inoue</surname>
            <given-names>Jun-Ichiro</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">â¡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nakano</surname>
            <given-names>Hiroyasu</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">Â§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okazaki</surname>
            <given-names>Kenji</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">â</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okumura</surname>
            <given-names>Ko</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">Â§</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Tadashi</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">â¡</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nagaoka</surname>
            <given-names>Hitoshi</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">*</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Takemori</surname>
            <given-names>Toshitada</given-names>
          </name>
          <xref ref-type="aff" rid="N0x3c916d0N0x1fbb010">*</xref>
        </contrib>
      </contrib-group>
      <aff id="N0x3c916d0N0x1fbb010">
<label>*</label>Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162, Japan; <label>â¡</label>Department of Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shiroganedai, Minato-ku, Tokyo 108, Japan; <label>Â§</label>Department of Immunology, School of Medicine, Juntendo University, 2-1-1, Hongo, Bunkyo-ku, Tokyo 113, Japan; <label>â</label>CREST (Core Research for Evolutional Science and Technology) of Japan Science and Technology Corporation (JST), and <label>Â¶</label>Department of Molecular Biology, Biomolecular Engineering Research Institute, 6-2-3 Furuedai, Suita-shi, Osaka-fu 565, Japan</aff>
      <author-notes>
        <fn>
          <p>Address correspondence to Dr. T. Takemori, Department of Immunology, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-Ku, Tokyo 162, Japan. Phone: 81-3-5285-1156; Fax: 81-3-5285-1156; E-mail: <email>ttoshi@nih.go.jp</email>
</p>
        </fn>
      </author-notes>
      <pub-date pub-type="ppub">
        <day>19</day>
        <month>1</month>
        <year>1998</year>
      </pub-date>
      <volume>187</volume>
      <issue>2</issue>
      <fpage>237</fpage>
      <lpage>244</lpage>
      <history>
        <date date-type="received">
          <day>12</day>
          <month>9</month>
          <year>1997</year>
        </date>
      </history>
      <permissions>
        <copyright-year>1998</copyright-year>
        <license license-type="openaccess">
          <license-p>This article is distributed under the terms of an AttributionâNoncommercialâShare AlikeâNo Mirror Sites license for the first six months after the publication date (see <ext-link ext-link-type="uri" xlink:href="http://www.rupress.org/terms">http://www.rupress.org/terms</ext-link>). After six months it is available under a Creative Commons License (AttributionâNoncommercialâShare Alike 4.0 Unported license, as described at <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>CD40 activates nuclear factor kappa B (NFÎºB) and the mitogen-activated protein kinase (MAPK) subfamily, including extracellular signalâregulated kinase (ERK). The CD40 cytoplasmic tail interacts with tumor necrosis factor receptorâassociated factor (TRAF)2, TRAF3, TRAF5, and TRAF6. These TRAF proteins, with the exception of TRAF3, are required for NFÎºB activation. Here we report that transient expression of TRAF6 stimulated both ERK and NFÎºB activity in the 293 cell line. Coexpression of the dominant-negative H-Ras did not affect TRAF6-mediated ERK activity, suggesting that TRAF6 may activate ERK along a Ras-independent pathway. The deletion mutant of TRAF6 lacking the NH<sub>2</sub>-terminal domain acted as a dominant-negative mutant to suppress ERK activation by full-length CD40 and suppress prominently ERK activation by a deletion mutant of CD40 only containing the binding site for TRAF6 in the cytoplasmic tail (CD40Î246). Transient expression of the dominant-negative H-Ras significantly suppressed ERK activation by full-length CD40, but marginally suppressed ERK activation by CD40Î246, compatible with the possibility that TRAF6 is a major transducer of ERK activation by CD40Î246, whose activity is mediated by a Ras-independent pathway. These results suggest that CD40 activates ERK by both a Ras-dependent pathway and a Ras-independent pathway in which TRAF6 could be involved.</p>
      </abstract>
    </article-meta>
  </front>
  <body>
    <p>CD40 is a cell-surface glycoprotein on B lymphocytes, dendritic cells, follicular dendritic cells, and thymic epithelial cells (<xref rid="B1" ref-type="bibr">1</xref>), and a member of the TNF-Î± receptor superfamily that includes 55- and 75-kD TNF receptors (TNFR1 and TNFR2, respectively), CD30 receptor, low-affinity nerve growth factor receptor, lymphotoxin Î² receptor (LTÎ²R), and Fas antigen (<xref rid="B1" ref-type="bibr">1</xref>).</p>
    <p>The cytoplasmic domain of the TNFR superfamily members lacks sequences indicative of catalytic activity, but is associated with a signal transducer, TNFR-associated factor (TRAF; reference <xref rid="B2" ref-type="bibr">2</xref>). The cytoplasmic domain of human CD40 consists of 62 amino acids at positions 196â257 and is associated with TRAF2, TRAF3, TRAF5, and TRAF6 (<xref rid="B3" ref-type="bibr">3</xref>â<xref rid="B9" ref-type="bibr">9</xref>) and Janus kinase (Jak)3 (<xref rid="B10" ref-type="bibr">10</xref>); the membrane proximal region of the cytoplasmic tail of CD40 contains a proline-rich region at positions 202â209 that is crucial for Jak3 binding (<xref rid="B10" ref-type="bibr">10</xref>). TRAF6 binds to the NH<sub>2</sub>-terminal cytoplasmic tail of CD40 at positions 210â225, although the possibility can not be excluded that full association of TRAF6 with CD40 may also require the COOH-terminal part at positions 226â249 (<xref rid="B9" ref-type="bibr">9</xref>). TRAF2, TRAF3, and TRAF5 bind to the COOH-terminal CD40 cytoplasmic domain at positions 226â249 (<xref rid="B9" ref-type="bibr">9</xref>), containing a minimum element, designated TIMct, responsible for TRAF2 and TRAF3 binding and signal transduction mediating nuclear factor kappa B (NFÎºB) activation (<xref rid="B7" ref-type="bibr">7</xref>).</p>
    <p>Stimulation of CD40 results in activation of protein tyrosine kinases (PTKs), NFÎºB, the mitogen-activated protein kinase (MAPK), and Jak3/signal transducers and activators of transcription (STAT)3 (<xref rid="B10" ref-type="bibr">10</xref>â<xref rid="B18" ref-type="bibr">18</xref>), and it mediates critical biological effects in B cell growth, survival, and differentiation (<xref rid="B19" ref-type="bibr">19</xref>â<xref rid="B27" ref-type="bibr">27</xref>). It is known that TRAF2 and TRAF5 play a role in NFÎºB activation in signaling through CD40, as well as TNFR1, TNFR2, CD30, and lymphotoxin Î² receptor (<xref rid="B6" ref-type="bibr">6</xref>â<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B28" ref-type="bibr">28</xref>â<xref rid="B32" ref-type="bibr">32</xref>). TRAF6 participates in NFÎºB activation signaled by CD40 and IL-1 receptor (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B33" ref-type="bibr">33</xref>). The TRAF family is characterized by a homologous COOH-terminal TRAF-COOH (TRAF-C) domain, an Î±-helical TRAF-NH<sub>2</sub> (TRAF-N) domain, and an NH<sub>2</sub>-terminal RING finger with the exception of TRAF1 (<xref rid="B2" ref-type="bibr">2</xref>â<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B33" ref-type="bibr">33</xref>). The effector function of TRAF2 and TRAF5 toward NFÎºB activation is mediated by its NH<sub>2</sub>-terminal RING finger domain (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B30" ref-type="bibr">30</xref>), whereas that of TRAF6 is mediated by the RING finger and zinc fingers (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B33" ref-type="bibr">33</xref>).</p>
    <p>It has been reported that TRAF2 stimulates c-jun NH<sub>2</sub>-terminal kinase (JNK) activity in TNFR1 signaling (<xref rid="B34" ref-type="bibr">34</xref>â<xref rid="B36" ref-type="bibr">36</xref>), leading to the idea that TRAF2 may also play a role in JNK activation by CD40 (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). However, the signaling pathway coupling CD40 to extracellular signal-regulated kinase (ERK) activation has remained unknown. To investigate which TRAF proteins might participate in ERK activation, we have performed transient transfection experiments in the human embryonic kidney 293 cell line. In the present study, we demonstrate that TRAF6 plays a role as a signal transducer in ERK activation by CD40, probably along a Ras-independent pathway.</p>
    <sec sec-type="materials|methods" id="MaterialsMethods">
      <title>Materials and Methods</title>
      <sec disp-level="3">
        <title>Cell Culture.</title>
        <p>Human embryonic kidney cell line 293 was maintained in DME supplemented with 10% FCS, 200 mM <sc>l</sc>-glutamine, and penicillin/streptomycin.</p>
      </sec>
      <sec disp-level="3">
        <title>Plasmid Construction.</title>
        <p>TRAF2, TRAF3, and human CD40 cDNA were obtained by the reverse transcription PCR (RT-PCR) by use of messenger RNA purified from B cell lymphomas, WEHI231 and Raji, with primers flanking the entire coding region, and then cloned into pMIKHygB, a gift from Dr. K. Maruyama (Tokyo Medical and Dental University, Tokyo, Japan). Deletion mutants of TRAF2 that lack a RING finger motif (amino acids [aa] 87â501) and the TRAF-C domain (aa 352â501) were constructed by PCR. Isolation of TRAF5 and TRAF6 cDNAs and construction of the expression vectors coding full-length TRAF5, full-length TRAF6, and the TRAF-C of TRAF6 were reported previously (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B30" ref-type="bibr">30</xref>). A deletion mutant of human CD40, designated CD40Î246, that removes 32 aa at positions 226â257 from the cytoplasmic tail was previously described (<xref rid="B9" ref-type="bibr">9</xref>). Dominant-negative Raf-1 (aa 1â258) was constructed by reverse transcription PCR, according to Schaap et al. (<xref rid="B37" ref-type="bibr">37</xref>). Dominant-negative N17Ras (<xref rid="B38" ref-type="bibr">38</xref>) and glutathione-S-transferase (GST) fusion ERK2 (pGSTM1) were provided by Dr. G.M. Cooper (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA) and Dr. K. Takishima (National Defense Medical College, Saitama, Japan), respectively. Construction of a dominant-negative mutant of MAPK/ERK-activating kinase (MEK)1, designated MEK1<sup>DN</sup>, and a constitutively activated mutant of MEK1, designated MEK1<sup>EE</sup>, was previously described (<xref rid="B39" ref-type="bibr">39</xref>). All cDNA fragments were subcloned into pMIKHygB.</p>
        <p>ERK-dependent activator and reporter constructs were prepared according to Seth et al. (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In brief, the fusion of the GAL4 DNA-binding domain and the nuclear localization signal (aa 1â147) and NH<sub>2</sub>-terminal transcriptional activation region of c-Myc (aa 2â103) were constructed in vector pGBT9 (<named-content content-type="company" xlink:href="clontech">Clontech</named-content>, Palo Alto, CA), and its HindIII-SalI fragment was digested and subcloned into pMIKHygB, designated pGAL4MycN. A firefly luciferase reporter containing two copies of the GAL4 binding site adjacent to a thymidine kinase promoter was constructed into pGL2 (<named-content content-type="company" xlink:href="promega">Promega</named-content>, Madison, WI), designated pGAL4tkLuc. A previous study by Seth et al. (<xref rid="B41" ref-type="bibr">41</xref>) showed that, in cotransfected cells with the GAL4âc-Myc fusion construct and luciferase reporter, the phosphorylation state of the NH<sub>2</sub>-terminal c-Myc transactivation domain was increased in an ERK-dependent manner, resulting in an increase in the activity of the luciferase reporter gene (<xref rid="B41" ref-type="bibr">41</xref>). Therefore, this ERK-dependent activator and reporter system allows one to monitor ERK activity by measuring the luciferase reporter activity. NFÎºB-dependent luciferase constructs containing three copies of an NFÎºB binding site from immunogloblin Îº light chain enhancer and the thymidine kinase promoter was constructed into pGL2, designed pkBtkLuc. All cDNAs and constructs were confirmed by DNA sequencing.</p>
      </sec>
      <sec disp-level="3">
        <title>In Vitro MAPK Assay.</title>
        <p>An in vitro kinase assay for endogenous ERK activity was performed as previously described (<xref rid="B17" ref-type="bibr">17</xref>). For estimating exogenous ERK2 kinase activity, 293 cells were cotransfected with 1 Î¼g of GST-ERK2 and various amounts of plasmid constructs by the calcium phosphate coprecipitation method. The total amount of DNA was adjusted with empty vector at 10 Î¼g. When 293 cells were cotransfected with 1 Î¼g of CD40 cDNA, the cells were stimulated with anti-CD40 mAb (2 Î¼g/ml) 24 h after transfection. In some experiments, cells were analyzed for the expression of CD40 on the surface by FACScan<sup>Â®</sup> (<named-content content-type="company" xlink:href="becton">Becton Dickinson</named-content>, Mountain View, CA) with FITC-conjugated antiâhuman CD40 mAb (5C3; <named-content content-type="company" xlink:href="pharmingen">PharMingen</named-content>, San Diego, CA). The cell lysates were incubated with glutathione-coupled Sepharose 4B (<named-content content-type="company" xlink:href="pharmacia">Pharmacia</named-content>, Uppsala, Sweden) at 4Â°C for 1 h. The Sepharose beads were pelleted down by centrifugation and washed twice with lysis buffer and with Tris-buffered saline (10 mM Tris-HCl, pH 7.2, 100 mM NaCl) supplemented with 5 mM benzamidine and 1 mM Na<sub>3</sub>VO<sub>4</sub>. The GST-ERK2 immobilized on Sepharose was directly subjected to a kinase reaction as previously described (<xref rid="B17" ref-type="bibr">17</xref>).</p>
      </sec>
      <sec disp-level="3">
        <title>Luciferase Assay.</title>
        <p>Cells were cotransfected with either full-length CD40 or CD40Î246 and ERK-dependent activator and reporter plasmids consisted of 500 ng of pGAL4tkLuc and 100 ng of pGAL4MycN, or NFÎºB-dependent plasmid of 20 ng of pkBtkLuc, 1 Î¼g of Î²-actin Î²-galactosidase (Î²-gal), and various amounts of expression plasmids by the calcium phosphate coprecipitation method. Total amounts of DNA were adjusted with empty vector at 10 Î¼g. The cells were stimulated with anti-CD40 mAb 24 h after transfection. The cells were lysed in PicaGene<sup>TM</sup> Cell Culture Lysis Reagent LCÎ² (Toyo Ink, Tokyo, Japan) 24 h after incubation, and luciferase activity was measured by use of a luciferase assay kit, PicaGene<sup>TM</sup> (Toyo Ink), followed by normalization of transfection efficiency by Î²-gal activity.</p>
      </sec>
    </sec>
    <sec id="ResultsDiscussion">
      <title>Results and Discussion</title>
      <sec disp-level="4">
        <title>TRAF6 Is a Signal Transducer of Both ERK and NFÎºB Activation.</title>
        <p>Overexpression of TRAF2, TRAF5, and TRAF6 results in its aggregation and causes activation of the NFÎºB signaling pathway, which could be similar to that induced by ligand-triggered receptor aggregation (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B33" ref-type="bibr">33</xref>). Therefore, to investigate which TRAF proteins might participate in ERK activation, we cotransfected human embryonic kidney 293 cells with various TRAF expression vectors and an GST-ERK2 fusion construct. After transfection, the GSTâERK2 fusion protein was precipitated by use of glutatione Sepharose 4B from the cell lysate, and the ERK activity was analyzed by an in vitro kinase assay, with myelin basic protein (MBP) used as an exogenous substrate. As shown in Fig. <xref ref-type="fig" rid="F1">1</xref>
<italic>A</italic>, transient expression of full-length TRAF6, but not TRAF2, TRAF3, or TRAF5, stimulated exogenous ERK activity approximately fivefold above the vector control, suggesting that transient expression of TRAF6 stimulates ERK activity in the 293 cell line. </p>
        <p>ERK is known to phosphorylate target protein within the cytosol (<xref rid="B42" ref-type="bibr">42</xref>), whereas, under certain conditions, ERK translocates to the nucleus to phosphorylate the nuclear substrate (<xref rid="B41" ref-type="bibr">41</xref>, <xref rid="B43" ref-type="bibr">43</xref>â<xref rid="B45" ref-type="bibr">45</xref>). To investigate the effect of various TRAF proteins on ERK activity in the nucleus, we used an ERK- dependent activator and reporter system, established by Davis and coworkers (40, 41, and see Materials and Methods). Human 293 cells were transiently transfected with various TRAF expression vectors, together with an ERK-dependent activator, a fusion construct of the GAL4 DNA-binding domain and the nuclear localization signal/NH<sub>2</sub>-terminal transactivation domain of c-Myc, and a luciferase reporter plasmid containing GAL4 binding sites adjacent to a thymidine kinase promoter, as an ERK-dependent reporter (<xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B41" ref-type="bibr">41</xref>). In addition, to confirm the activity of TRAF proteins, we cotransfected 293 cells with various TRAF expression vectors and the NFÎºB-dependent luciferase reporter.</p>
        <p>As shown in Fig. <xref ref-type="fig" rid="F1">1</xref>
<italic>B a</italic>, transient expression of full-length TRAF6 triggered activation of the cotransfected ERK-dependent reporter in a dose-dependent manner to a maximum of approximately fourfold above the vector control, whereas a deletion of the RING finger and zinc fingers of TRAF6 (TRAF-C) abolished the activity of ERK activation. Consistent with previous reports (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B33" ref-type="bibr">33</xref>), transient expression of full-length TRAF6, but not TRAF-C of TRAF6, caused NFÎºB activation in the 293 cell line (Fig. <xref ref-type="fig" rid="F1">1</xref>
<italic>B b</italic>), suggesting that TRAF6 stimulates both ERK and NFÎºB activity through its NH<sub>2</sub>-terminal region containing the RING finger and zinc fingers. Parallel experiments showed that transient expression of full-length TRAF2 and TRAF5 had no effect on ERK activity, whereas it stimulated NFÎºB activity efficiently (Fig. <xref ref-type="fig" rid="F1">1</xref>
<italic>C</italic>; 6, 8, 30â32). In this context, previous reports also ruled out the role of TRAF2 in ERK activation (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Transient expression of TRAF3 stimulated neither ERK nor NFÎºB activity, in agreement with previous reports (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B34" ref-type="bibr">34</xref>). Taken together, these results suggest that TRAF6, but not TRAF2, TRAF3, or TRAF5, is a transducer of both ERK and NFÎºB activation.</p>
      </sec>
      <sec disp-level="4">
        <title>TRAF6 Stimulates ERK That Is Largely Independent of Ras.</title>
        <p>The Ras-dependent protein kinase cascade leading from various receptors to ERK is dependent on the protein kinase Raf-1, which activates a dual-specificity kinase, MEK (<xref rid="B42" ref-type="bibr">42</xref>). To investigate the role of Ras, Raf-1, and MEK1 in TRAF6-mediated ERK activation, we cotransfected 293 cells with a full-length TRAF6 and ERK-dependent activator and reporter, or GST-ERK, together with a dominant-negative mutant of H-Ras (N17Ras; 38), c-Raf-1, which contains only the NH<sub>2</sub>-terminal regulatory domain (DNRaf; 37), or MEK1, in which Asp<sup>208</sup> was replaced with Ala (MEK1<sup>DN</sup>; 39). Some experiments were performed in parallel with the experiments depicted in Fig. <xref ref-type="fig" rid="F4">4</xref>. As shown in Fig. <xref ref-type="fig" rid="F2">2</xref>, coexpression of N17Ras had no effect on the activity of the cotransfected ERK-dependent reporter (Fig. <xref ref-type="fig" rid="F2">2</xref>
<italic>A</italic>) or on the exogenous ERK kinase activity (Fig. <xref ref-type="fig" rid="F2">2</xref>
<italic>B</italic>), which were increased five- to sixfold above the vector control by transient expression of TRAF6. The results suggest that TRAF6 may stimulate ERK activity along a Ras-independent pathway. </p>
        <p>The dominant-negative DNRaf and MEK1<sup>DN</sup> suppressed TRAF6-mediated ERK activity in the 293 cell line, but not entirely (Fig. <xref ref-type="fig" rid="F2">2</xref>, <italic>A</italic> and <italic>B</italic>). Although ERK activation is essentially induced by growth factors via a Ras-mediated pathway (<xref rid="B42" ref-type="bibr">42</xref>), the result could be interpreted as evidence that the diversified signal cascades regulate ERK activity, sometimes in a cell-typeâspecific manner, via c-Raf-1 and other possible MAPK kinase kinase in a Ras-independent fashion (<xref rid="B46" ref-type="bibr">46</xref>â<xref rid="B51" ref-type="bibr">51</xref>).</p>
      </sec>
      <sec disp-level="4">
        <title>TRAF6 Is Involved in ERK Activation in CD40 Signaling.</title>
        <p>The truncated mutant of TRAF proteins that lack the RING finger or the RING finger and zinc fingers acts as a transdominant-negative mutant to suppress NFÎºB activation in signaling through TNFR1, TNFR2, IL-1R, CD30, and CD40 receptor (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>), in which the dominant-negative mutant may act specifically by replacing the corresponding endogenous wild-type TRAF protein.</p>
        <p>To investigate whether TRAF6 could be involved in ERK activation by CD40, we cotransfected 293 cells with the TRAF-C of TRAF6 and ERK-dependent activator and reporter, or GST-ERK, together with full-length CD40 cDNA. Because a previous report suggested that the NH<sub>2</sub>-terminal CD40 cytoplasmic tail at positions 210â225 could be essential for TRAF6 binding and could function for NFÎºB activation (<xref rid="B9" ref-type="bibr">9</xref>), the involvement of TRAF6 in ERK activation by CD40 was also investigated by transient transfection of the TRAF-C of TRAF6 and ERK-dependent activator and reporter, or GST-ERK, into 293 cells coexpressing a deletion mutant of CD40, CD40Î246 (<xref rid="B9" ref-type="bibr">9</xref>), that removes the COOH-terminal cytoplasmic tail at positions 226â257. Previous results showed that TRAF6 interacts with the CD40Î246 construct in vivo (<xref rid="B9" ref-type="bibr">9</xref>).</p>
        <p>As shown in Fig. <xref ref-type="fig" rid="F3">3</xref>, <italic>A</italic> and <italic>B</italic>, cross-linking of full-length CD40 and CD40Î246 caused ERK activation approximately four- to sixfold above the level of unstimulated cells, comparable to the magnitude of the endogenous ERK activity that was transiently increased in 293 transfectants which constitutively expressed CD40 after stimulation with anti-CD40 mAb (data not shown). As shown in Fig. <xref ref-type="fig" rid="F3">3</xref>, <italic>A</italic> (<italic>a</italic>) and <italic>B</italic> both ERK-dependent reporter activity (Fig. <xref ref-type="fig" rid="F3">3</xref>
<italic>A</italic>) and the exogenous ERK kinase activity (Fig. <xref ref-type="fig" rid="F3">3</xref>
<italic>B</italic>) mediated by full-length CD40 were suppressed by coexpression of TRAF-C of TRAF6 in a dose-dependent manner to a maximum of 30â35% of inhibition, compatible with the notion that TRAF6-dependent and -independent pathways could be involved in ERK activation by CD40 (see below). Coexpression of the TRAF-C of TRAF6 caused prominent suppression of ERK activity mediated by cross-linking of CD40Î246 in a dose-dependent manner, suggesting a major role of TRAF6 in ERK activation by CD40Î246. It is not likely that the transdominant-negative mutant of TRAF6 nonspecifically diminished the activity of the ERK-dependent activator and reporter, because activation of the ERK-dependent reporter mediated by coexpression of catalytically active MEK1 (<xref rid="B39" ref-type="bibr">39</xref>) in the 293 cell line was not prevented by coexpression of TRAF-C of TRAF6 (data not shown). </p>
        <p>In control experiments, transient expression of the TRAF-C of TRAF6 caused prominent suppression of the activity of cotransfected NFÎºB-dependent reporter mediated by CD40Î246 in the 293 cell line (Fig. <xref ref-type="fig" rid="F3">3</xref>
<italic>C b</italic>), consistent with previous reports (<xref rid="B9" ref-type="bibr">9</xref>). In contrast to ERK activation, the activation of NFÎºB activity by full-length CD40 was greater than that by CD40Î246, and â¼50% of the activity was suppressed by coexpression of the TRAF-C of TRAF6 (Fig. <xref ref-type="fig" rid="F3">3</xref>
<italic>C a</italic>). Because of a similar frequency and the level of expression of full-length CD40 and CD40Î246 in the 293 cell line in transient transfection assays (data not shown), the results seem compatible with the notion that distinct regions of the CD40 cytoplasmic domain could be required for full activation of NFÎºB in the 293 cell line.</p>
      </sec>
      <sec disp-level="4">
        <title>CD40 Activates ERK by the Ras-dependent Pathway and Ras-independent Pathway in which TRAF6 Could Be Involved.</title>
        <p>To investigate the role of Ras, Raf-1, and MEK in ERK activation by CD40, we cotransfected 293 cells with the ERK-dependent activator and reporter, or NFÎºB-dependent reporter as a control, and with N17Ras, DNRaf, or MEK1<sup>DN</sup>, together with either full-length CD40 or CD40Î246. The experiments were performed in parallel with some of the experiments depicted in Fig. <xref ref-type="fig" rid="F2">2</xref>
<italic>A.</italic> Cotransfection of N17Ras, DNRaf, and MEK1<sup>DN</sup> caused â¼70% inhibition of ERK activity mediated by cross-linking of full-length CD40 (Fig. <xref ref-type="fig" rid="F4">4</xref>
<italic>A a</italic>). In contrast, coexpression of N17Ras and MEK1<sup>DN</sup> did not affect NFÎºB activation by both full-length CD40 and CD40Î246, whereas DNRaf marginally suppressed NFÎºB activation (Fig. <xref ref-type="fig" rid="F4">4</xref>
<italic>B</italic>). In conjunction with the previous observation indicating activation of the Ras-mediated pathway by CD40 stimulation in B cells (<xref rid="B52" ref-type="bibr">52</xref>), the results support the possibility that the Ras-Raf-MEKâmediated pathway could be involved in ERK activation, but not NFÎºB, by cross-linking of CD40. Transient expression of N17Ras resulted in â¼30% inhibition of ERK activity mediated by CD40Î246, compatible with the notion that TRAF6 is a major transducer of ERK activation by CD40Î246, whose activity is mediated by a Ras-independent pathway.</p>
        <p>Taken together, these results support the possibility that CD40 may activate ERK via Ras-dependent and -independent pathways in which TRAF6 could be involved. The inhibition by a dominant-negative mutant of MEK1 in ERK activity by full-length CD40 was more prominent than in ERK activity mediated by TRAF6 and by CD40Î246, in which TRAF6 may play a major role. Because the MEK isoforms MEK1 and MEK2 are an ERK-specific kinase (<xref rid="B53" ref-type="bibr">53</xref>), these results might imply that preferential usage of MEK isoforms would differ in TRAF6-dependent and -independent pathways in CD40 signaling. In this context, it has been suggested that the signaling pathways leading to activation of MEK isoforms appear to differ, and that each MEK isoform could be preferentially used in a particular external stimulus in a certain type of cell (<xref rid="B54" ref-type="bibr">54</xref>â<xref rid="B56" ref-type="bibr">56</xref>). Further study is needed to clarify the signaling pathway coupling TRAF6 to ERK activation.</p>
        <p>Given that full ERK activity is stimulated through TRAF6-dependent and -independent pathways in CD40 signaling, a similar extent of ERK activation by full-length CD40 and CD40Î246 in the 293 cell line led to the idea that ERK activity could be regulated in full-length CD40 signaling in 293 cells, probably via activation of MAPK phosphatase or downregulation of MEK activity (<xref rid="B57" ref-type="bibr">57</xref>â<xref rid="B60" ref-type="bibr">60</xref>). In contrast to ERK activation in murine splenic resting B cells (<xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B18" ref-type="bibr">18</xref>), it was reported that CD40 stimulation did not cause ERK activation in human tonsil B cells (<xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B16" ref-type="bibr">16</xref>). Whether ERK activation is regulated in CD40 signaling, depending on the maturation stage of B cells, would be worth analyzing.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <p>We are grateful to Drs. G.M. Cooper (Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA), K. Maruyama (Tokyo Medical and Dental University, Tokyo, Japan), and K. Takishima (National Defense Medical College, Saitama, Japan) for reagents. We are also grateful to Drs. Tsunetsugu-Yokota and Z. Matsuda (NIID, Tokyo, Japan) for helpful discussions and reading of the manuscript, and to Mr. H. Shimizu, Ms. M. Takizawa, and K. Ishii for technical help.</p>
      <p>This work was supported by a grant from the Agency of Technology and Science of the Japanese government and partly from the Ministry of Education and Science and Japanese Human Sciences Foundation to T. Takemori.</p>
    </ack>
    <fn-group>
      <fn id="FN1">
        <label>1</label>
        <p>
<italic>Abbreviations used in this paper:</italic> Î²-gal, Î²-galactosidase; aa, amino acids; DN, dominant negative; ERK, extracellular signalâregulated kinase; GST, glutathione-S-transferase; Jak, Janus kinase; JNK, c-jun NH<sub>2</sub>-terminal kinase; MAPK, mitogen-activated protein kinase; MBP, myelin basic protein; MEK, MAPK/ERK-activating kinase; NFÎºB, nuclear factor kappa B; TRAF, TNFR-associated factor; TRAF-C, TRAF-COOH; TRAF-N, TRAF-NH<sub>2</sub>.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B1">
        <label>1</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banchereau</surname><given-names>J</given-names></name><name><surname>Bazan</surname><given-names>F</given-names></name><name><surname>Blanchard</surname><given-names>D</given-names></name><name><surname>Briere</surname><given-names>F</given-names></name><name><surname>Galizzi</surname><given-names>JP</given-names></name><name><surname>van Kooten</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>YJ</given-names></name><name><surname>Rousset</surname><given-names>F</given-names></name><name><surname>Saeland</surname><given-names>S</given-names></name></person-group>
<article-title>The CD40 antigen and its ligand</article-title>
<source>Annu Rev Immunol</source>
<year>1994</year>
<volume>12</volume>
<fpage>881</fpage>
<lpage>922</lpage>
<?supplied-pmid 7516669?><pub-id pub-id-type="pmid">7516669</pub-id></element-citation>
      </ref>
      <ref id="B2">
        <label>2</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothe</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>SC</given-names></name><name><surname>Henzel</surname><given-names>WJ</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group>
<article-title>A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor</article-title>
<source>Cell</source>
<year>1994</year>
<volume>78</volume>
<fpage>681</fpage>
<lpage>692</lpage>
<?supplied-pmid 8069916?><pub-id pub-id-type="pmid">8069916</pub-id></element-citation>
      </ref>
      <ref id="B3">
        <label>3</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hu</surname><given-names>HM</given-names></name><name><surname>O'Rourke</surname><given-names>K</given-names></name><name><surname>Boguski</surname><given-names>MS</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name></person-group>
<article-title>A novel RING finger protein interacts with the cytoplasmic domain of CD40</article-title>
<source>J Biol Chem</source>
<year>1994</year>
<volume>269</volume>
<fpage>30069</fpage>
<lpage>30072</lpage>
<?supplied-pmid 7527023?><pub-id pub-id-type="pmid">7527023</pub-id></element-citation>
      </ref>
      <ref id="B4">
        <label>4</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sato</surname><given-names>T</given-names></name><name><surname>Irie</surname><given-names>S</given-names></name><name><surname>Reed</surname><given-names>JC</given-names></name></person-group>
<article-title>A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40</article-title>
<source>FEBS Lett</source>
<year>1995</year>
<volume>358</volume>
<fpage>113</fpage>
<lpage>118</lpage>
<?supplied-pmid 7530216?><pub-id pub-id-type="pmid">7530216</pub-id></element-citation>
      </ref>
      <ref id="B5">
        <label>5</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Cleary</surname><given-names>AM</given-names></name><name><surname>Ye</surname><given-names>ZS</given-names></name><name><surname>Hong</surname><given-names>DI</given-names></name><name><surname>Lederman</surname><given-names>S</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>Involvement of CRAF1, a relative of TRAF, in CD40 signaling</article-title>
<source>Science</source>
<year>1995</year>
<volume>267</volume>
<fpage>1494</fpage>
<lpage>1498</lpage>
<?supplied-pmid 7533327?><pub-id pub-id-type="pmid">7533327</pub-id></element-citation>
      </ref>
      <ref id="B6">
        <label>6</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rothe</surname><given-names>M</given-names></name><name><surname>Sarma</surname><given-names>V</given-names></name><name><surname>Dixit</surname><given-names>VM</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group>
<article-title>TRAF2-mediated activation of NF-ÎºB by TNF receptor 2 and CD40</article-title>
<source>Science</source>
<year>1995</year>
<volume>269</volume>
<fpage>1424</fpage>
<lpage>1427</lpage>
<?supplied-pmid 7544915?><pub-id pub-id-type="pmid">7544915</pub-id></element-citation>
      </ref>
      <ref id="B7">
        <label>7</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cheng</surname><given-names>G</given-names></name><name><surname>Baltimore</surname><given-names>D</given-names></name></person-group>
<article-title>TANK, a co-inducer with TRAF2 of TNF- and CD40L-mediated NF-kappaB activation</article-title>
<source>Genes Dev</source>
<year>1996</year>
<volume>10</volume>
<fpage>963</fpage>
<lpage>973</lpage>
<?supplied-pmid 8608943?><pub-id pub-id-type="pmid">8608943</pub-id></element-citation>
      </ref>
      <ref id="B8">
        <label>8</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishida</surname><given-names>TK</given-names></name><name><surname>Tojo</surname><given-names>T</given-names></name><name><surname>Aoki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Ohishi</surname><given-names>T</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name></person-group>
<article-title>TRAF5, a novel tumor necrosis factor receptorâassociated factor family protein, mediates CD40 signaling</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1996</year>
<volume>93</volume>
<fpage>9437</fpage>
<lpage>9442</lpage>
<?supplied-pmid 8790348?><pub-id pub-id-type="pmid">8790348</pub-id></element-citation>
      </ref>
      <ref id="B9">
        <label>9</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Mizushima</surname><given-names>SI</given-names></name><name><surname>Azuma</surname><given-names>S</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Tojo</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Mosialos</surname><given-names>G</given-names></name><name><surname>Kieff</surname><given-names>E</given-names></name><etal/></person-group>
<article-title>Identification of TRAF6, a novel tumor necrosis factor receptorâassociated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>28745</fpage>
<lpage>28748</lpage>
<?supplied-pmid 8910514?><pub-id pub-id-type="pmid">8910514</pub-id></element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hanissian</surname><given-names>SH</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group>
<article-title>Jak3 is associated with CD40 and is critical for CD40 induction of gene expression in B cells</article-title>
<source>Immunity</source>
<year>1997</year>
<volume>6</volume>
<fpage>379</fpage>
<lpage>387</lpage>
<?supplied-pmid 9133417?><pub-id pub-id-type="pmid">9133417</pub-id></element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lalmanach</surname><given-names>GA</given-names></name><name><surname>Chiles</surname><given-names>TC</given-names></name><name><surname>Parker</surname><given-names>DC</given-names></name><name><surname>Rothstein</surname><given-names>TL</given-names></name></person-group>
<article-title>T cellâdependent induction of NF-kappa B in B cells</article-title>
<source>J Exp Med</source>
<year>1993</year>
<volume>177</volume>
<fpage>1215</fpage>
<lpage>1219</lpage>
<?supplied-pmid 8459216?><pub-id pub-id-type="pmid">8459216</pub-id></element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ren</surname><given-names>CL</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>SM</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group>
<article-title>Signal transduction via CD40 involves activation of lyn kinase and phosphatidylinositol-3-kinase, and phosphorylation of phospholipase C gamma 2</article-title>
<source>J Exp Med</source>
<year>1994</year>
<volume>179</volume>
<fpage>673</fpage>
<lpage>680</lpage>
<?supplied-pmid 7507510?><pub-id pub-id-type="pmid">7507510</pub-id></element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Faris</surname><given-names>M</given-names></name><name><surname>Gaskin</surname><given-names>F</given-names></name><name><surname>Parsons</surname><given-names>JT</given-names></name><name><surname>Fu</surname><given-names>SM</given-names></name></person-group>
<article-title>CD40 signaling pathway: anti-CD40 monoclonal antibody induces rapid dephosphorylation and phosphorylation of tyrosine-phosphorylated proteins including protein tyrosine kinase Lyn, Fyn, and Syk and the appearance of a 28-kD tyrosine phosphorylated protein</article-title>
<source>J Exp Med</source>
<year>1994</year>
<volume>179</volume>
<fpage>1923</fpage>
<lpage>1931</lpage>
<?supplied-pmid 7515102?><pub-id pub-id-type="pmid">7515102</pub-id></element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berberich</surname><given-names>I</given-names></name><name><surname>Shu</surname><given-names>GL</given-names></name><name><surname>Clark</surname><given-names>EA</given-names></name></person-group>
<article-title>Cross-linking CD40 on B cells rapidly activates nuclear factorâkappa B</article-title>
<source>J Immunol</source>
<year>1994</year>
<volume>153</volume>
<fpage>4357</fpage>
<lpage>4366</lpage>
<?supplied-pmid 7525701?><pub-id pub-id-type="pmid">7525701</pub-id></element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sakata</surname><given-names>N</given-names></name><name><surname>Patel</surname><given-names>HR</given-names></name><name><surname>Terada</surname><given-names>N</given-names></name><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name><name><surname>Gelfand</surname><given-names>EW</given-names></name></person-group>
<article-title>Selective activation of c-Jun kinase mitogen-activated protein kinase by CD40 on human B cells</article-title>
<source>J Biol Chem</source>
<year>1995</year>
<volume>270</volume>
<fpage>30823</fpage>
<lpage>30828</lpage>
<?supplied-pmid 8530526?><pub-id pub-id-type="pmid">8530526</pub-id></element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berberich</surname><given-names>I</given-names></name><name><surname>Shu</surname><given-names>G</given-names></name><name><surname>Siebelt</surname><given-names>F</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Kyriakis</surname><given-names>JM</given-names></name><name><surname>Clark</surname><given-names>EA</given-names></name></person-group>
<article-title>Cross-linking CD40 on B cells preferentially induces stress-activated protein kinases rather than mitogen-activated protein kinases</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1996</year>
<volume>15</volume>
<fpage>92</fpage>
<lpage>101</lpage>
<?supplied-pmid 8598210?><pub-id pub-id-type="pmid">8598210</pub-id></element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kashiwada</surname><given-names>M</given-names></name><name><surname>Kaneko</surname><given-names>Y</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Takemori</surname><given-names>T</given-names></name></person-group>
<article-title>Activation of mitogen-activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells</article-title>
<source>Eur J Immunol</source>
<year>1996</year>
<volume>26</volume>
<fpage>1451</fpage>
<lpage>1458</lpage>
<?supplied-pmid 8766546?><pub-id pub-id-type="pmid">8766546</pub-id></element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Baccam</surname><given-names>M</given-names></name><name><surname>Waters</surname><given-names>SB</given-names></name><name><surname>Pessin</surname><given-names>JE</given-names></name><name><surname>Bishop</surname><given-names>GA</given-names></name><name><surname>Koretzky</surname><given-names>GA</given-names></name></person-group>
<article-title>CD40 ligation results in protein kinase C-independent activation of ERK and JNK in resting murine splenic B cells</article-title>
<source>J Immunol</source>
<year>1996</year>
<volume>157</volume>
<fpage>1440</fpage>
<lpage>1447</lpage>
<?supplied-pmid 8759724?><pub-id pub-id-type="pmid">8759724</pub-id></element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Allen</surname><given-names>RC</given-names></name><name><surname>Armitage</surname><given-names>RJ</given-names></name><name><surname>Conley</surname><given-names>ME</given-names></name><name><surname>Rosenblatt</surname><given-names>H</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Copeland</surname><given-names>NG</given-names></name><name><surname>Bedell</surname><given-names>MA</given-names></name><name><surname>Edelhoff</surname><given-names>S</given-names></name><name><surname>Disteche</surname><given-names>CM</given-names></name><name><surname>Simoneaux</surname><given-names>DK</given-names></name><etal/></person-group>
<article-title>CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome</article-title>
<source>Science</source>
<year>1993</year>
<volume>259</volume>
<fpage>990</fpage>
<lpage>993</lpage>
<?supplied-pmid 7679801?><pub-id pub-id-type="pmid">7679801</pub-id></element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aruffo</surname><given-names>A</given-names></name><name><surname>Farrington</surname><given-names>M</given-names></name><name><surname>Hollenbaugh</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Milatovich</surname><given-names>A</given-names></name><name><surname>Nonoyama</surname><given-names>S</given-names></name><name><surname>Bajorath</surname><given-names>J</given-names></name><name><surname>Grosmaire</surname><given-names>LS</given-names></name><name><surname>Stenkamp</surname><given-names>R</given-names></name><name><surname>Neubauer</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome</article-title>
<source>Cell</source>
<year>1993</year>
<volume>72</volume>
<fpage>291</fpage>
<lpage>300</lpage>
<?supplied-pmid 7678782?><pub-id pub-id-type="pmid">7678782</pub-id></element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Korthauer</surname><given-names>U</given-names></name><name><surname>Graf</surname><given-names>D</given-names></name><name><surname>Mages</surname><given-names>HW</given-names></name><name><surname>Briere</surname><given-names>F</given-names></name><name><surname>Padayachee</surname><given-names>M</given-names></name><name><surname>Malcolm</surname><given-names>S</given-names></name><name><surname>Ugazio</surname><given-names>AG</given-names></name><name><surname>Notarangelo</surname><given-names>LD</given-names></name><name><surname>Levinsky</surname><given-names>RJ</given-names></name><name><surname>Kroczek</surname><given-names>RA</given-names></name></person-group>
<article-title>Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM</article-title>
<source>Nature</source>
<year>1993</year>
<volume>361</volume>
<fpage>539</fpage>
<lpage>541</lpage>
<?supplied-pmid 7679206?><pub-id pub-id-type="pmid">7679206</pub-id></element-citation>
      </ref>
      <ref id="B22">
        <label>22</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DiSanto</surname><given-names>JP</given-names></name><name><surname>Bonnefoy</surname><given-names>JY</given-names></name><name><surname>Gauchat</surname><given-names>JF</given-names></name><name><surname>Fischer</surname><given-names>A</given-names></name><name><surname>de Saint</surname><given-names>G</given-names></name><name><surname>Basile</surname></name></person-group>
<article-title>CD40 ligand mutations in X-linked immunodeficiency with hyper-IgM</article-title>
<source>Nature</source>
<year>1993</year>
<volume>361</volume>
<fpage>541</fpage>
<lpage>543</lpage>
<?supplied-pmid 8094231?><pub-id pub-id-type="pmid">8094231</pub-id></element-citation>
      </ref>
      <ref id="B23">
        <label>23</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fuleihan</surname><given-names>R</given-names></name><name><surname>Ramesh</surname><given-names>N</given-names></name><name><surname>Loh</surname><given-names>R</given-names></name><name><surname>Jabara</surname><given-names>H</given-names></name><name><surname>Rosen</surname><given-names>RS</given-names></name><name><surname>Chatila</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>SM</given-names></name><name><surname>Stamenkovic</surname><given-names>I</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group>
<article-title>Defective expression of the CD40 ligand in X chromosome-linked immunoglobulin deficiency with normal or elevated IgM</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1993</year>
<volume>90</volume>
<fpage>2170</fpage>
<lpage>2173</lpage>
<?supplied-pmid 7681587?><pub-id pub-id-type="pmid">7681587</pub-id></element-citation>
      </ref>
      <ref id="B24">
        <label>24</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kawabe</surname><given-names>T</given-names></name><name><surname>Naka</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Suematsu</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>N</given-names></name><name><surname>Kishimoto</surname><given-names>T</given-names></name><name><surname>Kikutani</surname><given-names>H</given-names></name></person-group>
<article-title>The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation</article-title>
<source>Immunity</source>
<year>1994</year>
<volume>1</volume>
<fpage>167</fpage>
<lpage>178</lpage>
<?supplied-pmid 7534202?><pub-id pub-id-type="pmid">7534202</pub-id></element-citation>
      </ref>
      <ref id="B25">
        <label>25</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castigli</surname><given-names>E</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name><name><surname>Davidson</surname><given-names>L</given-names></name><name><surname>Bottaro</surname><given-names>A</given-names></name><name><surname>Mizoguchi</surname><given-names>E</given-names></name><name><surname>Bhan</surname><given-names>AK</given-names></name><name><surname>Geha</surname><given-names>RS</given-names></name></person-group>
<article-title>CD40-deficient mice generated by recombination-activating gene-2âdeficient blastocyst complementation</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1994</year>
<volume>91</volume>
<fpage>12135</fpage>
<lpage>12139</lpage>
<?supplied-pmid 7527552?><pub-id pub-id-type="pmid">7527552</pub-id></element-citation>
      </ref>
      <ref id="B26">
        <label>26</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Foy</surname><given-names>TM</given-names></name><name><surname>Laman</surname><given-names>JD</given-names></name><name><surname>Elliott</surname><given-names>EA</given-names></name><name><surname>Dunn</surname><given-names>JJ</given-names></name><name><surname>Waldschmidt</surname><given-names>TJ</given-names></name><name><surname>Elsemore</surname><given-names>J</given-names></name><name><surname>Noelle</surname><given-names>RJ</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group>
<article-title>Mice deficient for the CD40 ligand (published erratum 1:613)</article-title>
<source>Immunity</source>
<year>1994</year>
<volume>1</volume>
<fpage>423</fpage>
<lpage>431</lpage>
<?supplied-pmid 7882172?><pub-id pub-id-type="pmid">7882172</pub-id></element-citation>
      </ref>
      <ref id="B27">
        <label>27</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Clark</surname><given-names>EA</given-names></name><name><surname>Ledbetter</surname><given-names>JA</given-names></name></person-group>
<article-title>How B and T cells talk to each other</article-title>
<source>Nature</source>
<year>1994</year>
<volume>367</volume>
<fpage>425</fpage>
<lpage>428</lpage>
<?supplied-pmid 8107800?><pub-id pub-id-type="pmid">8107800</pub-id></element-citation>
      </ref>
      <ref id="B28">
        <label>28</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hsu</surname><given-names>H</given-names></name><name><surname>Shu</surname><given-names>HB</given-names></name><name><surname>Pan</surname><given-names>MG</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group>
<article-title>TRADDâTRAF2 and TRADDâFADD interactions define two distinct TNF receptor 1 signal transduction pathways</article-title>
<source>Cell</source>
<year>1996</year>
<volume>84</volume>
<fpage>299</fpage>
<lpage>308</lpage>
<?supplied-pmid 8565075?><pub-id pub-id-type="pmid">8565075</pub-id></element-citation>
      </ref>
      <ref id="B29">
        <label>29</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gedrich</surname><given-names>RW</given-names></name><name><surname>Gilfillan</surname><given-names>MC</given-names></name><name><surname>Duckett</surname><given-names>CS</given-names></name><name><surname>Van Dongen</surname><given-names>DJ</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group>
<article-title>CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptorâassociated factor family of signal transducing proteins</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>12852</fpage>
<lpage>12858</lpage>
<?supplied-pmid 8662842?><pub-id pub-id-type="pmid">8662842</pub-id></element-citation>
      </ref>
      <ref id="B30">
        <label>30</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Oshima</surname><given-names>H</given-names></name><name><surname>Chung</surname><given-names>W</given-names></name><name><surname>Williams</surname><given-names>AL</given-names></name><name><surname>Ware</surname><given-names>CF</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name></person-group>
<article-title>TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>14661</fpage>
<lpage>14664</lpage>
<?supplied-pmid 8663299?><pub-id pub-id-type="pmid">8663299</pub-id></element-citation>
      </ref>
      <ref id="B31">
        <label>31</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Kandala</surname><given-names>G</given-names></name><name><surname>Liou</surname><given-names>ML</given-names></name><name><surname>Liou</surname><given-names>HC</given-names></name><name><surname>Choi</surname><given-names>Y</given-names></name></person-group>
<article-title>CD30/TNF receptorâassociated factor interaction: NF-kappa B activation and binding specificity</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1996</year>
<volume>93</volume>
<fpage>9699</fpage>
<lpage>9703</lpage>
<?supplied-pmid 8790394?><pub-id pub-id-type="pmid">8790394</pub-id></element-citation>
      </ref>
      <ref id="B32">
        <label>32</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>H</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Horie</surname><given-names>R</given-names></name><name><surname>Nagai</surname><given-names>M</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Yagita</surname><given-names>H</given-names></name><name><surname>Okumura</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>J</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name></person-group>
<article-title>Tumor necrosis factor receptorâassociated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFkappaB activation</article-title>
<source>J Biol Chem</source>
<year>1997</year>
<volume>272</volume>
<fpage>2042</fpage>
<lpage>2045</lpage>
<?supplied-pmid 8999898?><pub-id pub-id-type="pmid">8999898</pub-id></element-citation>
      </ref>
      <ref id="B33">
        <label>33</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cao</surname><given-names>Z</given-names></name><name><surname>Xiong</surname><given-names>J</given-names></name><name><surname>Takeuchi</surname><given-names>M</given-names></name><name><surname>Kurama</surname><given-names>T</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name></person-group>
<article-title>TRAF6 is a signal transducer for interleukin-1</article-title>
<source>Nature</source>
<year>1996</year>
<volume>383</volume>
<fpage>443</fpage>
<lpage>446</lpage>
<?supplied-pmid 8837778?><pub-id pub-id-type="pmid">8837778</pub-id></element-citation>
      </ref>
      <ref id="B34">
        <label>34</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Liu</surname><given-names>ZG</given-names></name><name><surname>Hsu</surname><given-names>H</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group>
<article-title>Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death</article-title>
<source>Cell</source>
<year>1996</year>
<volume>87</volume>
<fpage>565</fpage>
<lpage>576</lpage>
<?supplied-pmid 8898208?><pub-id pub-id-type="pmid">8898208</pub-id></element-citation>
      </ref>
      <ref id="B35">
        <label>35</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Natoli</surname><given-names>G</given-names></name><name><surname>Costanzo</surname><given-names>A</given-names></name><name><surname>Ianni</surname><given-names>A</given-names></name><name><surname>Templeton</surname><given-names>DJ</given-names></name><name><surname>Woodgett</surname><given-names>JR</given-names></name><name><surname>Balsano</surname><given-names>C</given-names></name><name><surname>Levrero</surname><given-names>M</given-names></name></person-group>
<article-title>Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway</article-title>
<source>Science</source>
<year>1997</year>
<volume>275</volume>
<fpage>200</fpage>
<lpage>203</lpage>
<?supplied-pmid 8985011?><pub-id pub-id-type="pmid">8985011</pub-id></element-citation>
      </ref>
      <ref id="B36">
        <label>36</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reinhard</surname><given-names>C</given-names></name><name><surname>Shamoon</surname><given-names>B</given-names></name><name><surname>Shyamala</surname><given-names>V</given-names></name><name><surname>Williams</surname><given-names>LT</given-names></name></person-group>
<article-title>Tumor necrosis factor Î±âinduced activation of c-jun N-terminal kinase is mediated by TRAF2</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1997</year>
<volume>16</volume>
<fpage>1080</fpage>
<lpage>1092</lpage>
<?supplied-pmid 9118946?><pub-id pub-id-type="pmid">9118946</pub-id></element-citation>
      </ref>
      <ref id="B37">
        <label>37</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schaap</surname><given-names>D</given-names></name><name><surname>van der Wal</surname><given-names>J</given-names></name><name><surname>Howe</surname><given-names>LR</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>van Blitterswijk</surname><given-names>WJ</given-names></name></person-group>
<article-title>A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras</article-title>
<source>J Biol Chem</source>
<year>1993</year>
<volume>268</volume>
<fpage>20232</fpage>
<lpage>20236</lpage>
<?supplied-pmid 8397201?><pub-id pub-id-type="pmid">8397201</pub-id></element-citation>
      </ref>
      <ref id="B38">
        <label>38</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Feig</surname><given-names>LA</given-names></name><name><surname>Cooper</surname><given-names>GM</given-names></name></person-group>
<article-title>Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP</article-title>
<source>Mol Cell Biol</source>
<year>1988</year>
<volume>8</volume>
<fpage>3235</fpage>
<lpage>3243</lpage>
<?supplied-pmid 3145408?><pub-id pub-id-type="pmid">3145408</pub-id></element-citation>
      </ref>
      <ref id="B39">
        <label>39</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okazaki</surname><given-names>K</given-names></name><name><surname>Sagata</surname><given-names>N</given-names></name></person-group>
<article-title>MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos</article-title>
<source>Oncogene</source>
<year>1995</year>
<volume>10</volume>
<fpage>1149</fpage>
<lpage>1157</lpage>
<?supplied-pmid 7700641?><pub-id pub-id-type="pmid">7700641</pub-id></element-citation>
      </ref>
      <ref id="B40">
        <label>40</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>E</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group>
<article-title>A phosphorylation site located in the NH2-terminal domain of c-Myc increases transactivation of gene expression</article-title>
<source>J Biol Chem</source>
<year>1991</year>
<volume>266</volume>
<fpage>23521</fpage>
<lpage>23524</lpage>
<?supplied-pmid 1748630?><pub-id pub-id-type="pmid">1748630</pub-id></element-citation>
      </ref>
      <ref id="B41">
        <label>41</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seth</surname><given-names>A</given-names></name><name><surname>Gonzalez</surname><given-names>FA</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Raden</surname><given-names>DL</given-names></name><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group>
<article-title>Signal transduction within the nucleus by mitogen-activated protein kinase</article-title>
<source>J Biol Chem</source>
<year>1992</year>
<volume>267</volume>
<fpage>24796</fpage>
<lpage>24804</lpage>
<?supplied-pmid 1332967?><pub-id pub-id-type="pmid">1332967</pub-id></element-citation>
      </ref>
      <ref id="B42">
        <label>42</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davis</surname><given-names>RJ</given-names></name></person-group>
<article-title>The mitogen-activated protein kinase signal transduction pathway</article-title>
<source>J Biol Chem</source>
<year>1993</year>
<volume>268</volume>
<fpage>14553</fpage>
<lpage>14556</lpage>
<?supplied-pmid 8325833?><pub-id pub-id-type="pmid">8325833</pub-id></element-citation>
      </ref>
      <ref id="B43">
        <label>43</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>RH</given-names></name><name><surname>Sarnecki</surname><given-names>C</given-names></name><name><surname>Blenis</surname><given-names>J</given-names></name></person-group>
<article-title>Nuclear localization and regulation of erk- and rsk-encoded protein kinases</article-title>
<source>Mol Cell Biol</source>
<year>1992</year>
<volume>12</volume>
<fpage>915</fpage>
<lpage>927</lpage>
<?supplied-pmid 1545823?><pub-id pub-id-type="pmid">1545823</pub-id></element-citation>
      </ref>
      <ref id="B44">
        <label>44</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lenormand</surname><given-names>P</given-names></name><name><surname>Sardet</surname><given-names>C</given-names></name><name><surname>Pages</surname><given-names>G</given-names></name><name><surname>L'Allemain</surname><given-names>G</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Pouyssegur</surname><given-names>J</given-names></name></person-group>
<article-title>Growth factors induce nuclear translocation of MAP kinases (p42mapk and p44mapk) but not of their activator MAP kinase kinase (p45mapkk) in fibroblasts</article-title>
<source>J Cell Biol</source>
<year>1993</year>
<volume>122</volume>
<fpage>1079</fpage>
<lpage>1088</lpage>
<?supplied-pmid 8394845?><pub-id pub-id-type="pmid">8394845</pub-id></element-citation>
      </ref>
      <ref id="B45">
        <label>45</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuda</surname><given-names>M</given-names></name><name><surname>Gotoh</surname><given-names>Y</given-names></name><name><surname>Nishida</surname><given-names>E</given-names></name></person-group>
<article-title>Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase</article-title>
<source>EMBO Eur Mol Bio Organ) J</source>
<year>1997</year>
<volume>16</volume>
<fpage>1901</fpage>
<lpage>1908</lpage>
<?supplied-pmid 9155016?><pub-id pub-id-type="pmid">9155016</pub-id></element-citation>
      </ref>
      <ref id="B46">
        <label>46</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burgering</surname><given-names>BM</given-names></name><name><surname>de Vries-Smits</surname><given-names>AMM</given-names></name><name><surname>Medema</surname><given-names>RH</given-names></name><name><surname>van Weeren</surname><given-names>PC</given-names></name><name><surname>Tertoolen</surname><given-names>LG</given-names></name><name><surname>Bos</surname><given-names>JL</given-names></name></person-group>
<article-title>Epidermal growth factor induces phosphorylation of extracellular signal-regulated kinase 2 via multiple pathways</article-title>
<source>Mol Cell Biol</source>
<year>1993</year>
<volume>13</volume>
<fpage>7248</fpage>
<lpage>7256</lpage>
<?supplied-pmid 8246947?><pub-id pub-id-type="pmid">8246947</pub-id></element-citation>
      </ref>
      <ref id="B47">
        <label>47</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Buscher</surname><given-names>D</given-names></name><name><surname>Hipskind</surname><given-names>RA</given-names></name><name><surname>Krautwald</surname><given-names>S</given-names></name><name><surname>Reimann</surname><given-names>T</given-names></name><name><surname>Baccarini</surname><given-names>M</given-names></name></person-group>
<article-title>Ras-dependent and -independent pathways target the mitogen-activated protein kinase network in macrophages</article-title>
<source>Mol Cell Biol</source>
<year>1995</year>
<volume>15</volume>
<fpage>466</fpage>
<lpage>475</lpage>
<?supplied-pmid 7799956?><pub-id pub-id-type="pmid">7799956</pub-id></element-citation>
      </ref>
      <ref id="B48">
        <label>48</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reuter</surname><given-names>CW</given-names></name><name><surname>Catling</surname><given-names>AD</given-names></name><name><surname>Jelinek</surname><given-names>T</given-names></name><name><surname>Weber</surname><given-names>MJ</given-names></name></person-group>
<article-title>Biochemical analysis of MEK activation in NIH3T3 fibroblasts. Identification of B-Raf and other activators</article-title>
<source>J Biol Chem</source>
<year>1995</year>
<volume>270</volume>
<fpage>7644</fpage>
<lpage>7655</lpage>
<?supplied-pmid 7706312?><pub-id pub-id-type="pmid">7706312</pub-id></element-citation>
      </ref>
      <ref id="B49">
        <label>49</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winston</surname><given-names>BW</given-names></name><name><surname>Lange</surname><given-names>CC</given-names></name><name><surname>Gardner</surname><given-names>AM</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name><name><surname>Riches</surname><given-names>DW</given-names></name></person-group>
<article-title>Tumor necrosis factor alpha rapidly activates the mitogen-activated protein kinase (MAPK) cascade in a MAPK kinase kinase-dependent, c-Raf-1âindependent fashion in mouse macrophages</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1995</year>
<volume>92</volume>
<fpage>1614</fpage>
<lpage>1618</lpage>
<?supplied-pmid 7878028?><pub-id pub-id-type="pmid">7878028</pub-id></element-citation>
      </ref>
      <ref id="B50">
        <label>50</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Lin</surname><given-names>TH</given-names></name><name><surname>Der</surname><given-names>CJ</given-names></name><name><surname>Juliano</surname><given-names>RL</given-names></name></person-group>
<article-title>Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>18122</fpage>
<lpage>18127</lpage>
<?supplied-pmid 8663436?><pub-id pub-id-type="pmid">8663436</pub-id></element-citation>
      </ref>
      <ref id="B51">
        <label>51</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cowen</surname><given-names>DS</given-names></name><name><surname>Sowers</surname><given-names>RS</given-names></name><name><surname>Manning</surname><given-names>DR</given-names></name></person-group>
<article-title>Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine 1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3âkinase, but to an inhibitor of phosphatidylcholine hydrolysis</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>22297</fpage>
<lpage>22300</lpage>
<?supplied-pmid 8798386?><pub-id pub-id-type="pmid">8798386</pub-id></element-citation>
      </ref>
      <ref id="B52">
        <label>52</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gulbins</surname><given-names>E</given-names></name><name><surname>Brenner</surname><given-names>B</given-names></name><name><surname>Schlottmann</surname><given-names>K</given-names></name><name><surname>Koppenhoefer</surname><given-names>U</given-names></name><name><surname>Linderkamp</surname><given-names>O</given-names></name><name><surname>Coggeshall</surname><given-names>KM</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name></person-group>
<article-title>Activation of the Ras signaling pathway by the CD40 receptor</article-title>
<source>J Immunol</source>
<year>1996</year>
<volume>157</volume>
<fpage>2844</fpage>
<lpage>2850</lpage>
<?supplied-pmid 8816388?><pub-id pub-id-type="pmid">8816388</pub-id></element-citation>
      </ref>
      <ref id="B53">
        <label>53</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zheng</surname><given-names>CF</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group>
<article-title>Properties of MEKs, the kinases that phosphorylate and activate the extracellular signalâregulated kinases</article-title>
<source>J Biol Chem</source>
<year>1993</year>
<volume>268</volume>
<fpage>23933</fpage>
<lpage>23939</lpage>
<?supplied-pmid 8226933?><pub-id pub-id-type="pmid">8226933</pub-id></element-citation>
      </ref>
      <ref id="B54">
        <label>54</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jelinek</surname><given-names>T</given-names></name><name><surname>Catling</surname><given-names>AD</given-names></name><name><surname>Reuter</surname><given-names>CW</given-names></name><name><surname>Moodie</surname><given-names>SA</given-names></name><name><surname>Wolfman</surname><given-names>A</given-names></name><name><surname>Weber</surname><given-names>MJ</given-names></name></person-group>
<article-title>RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2</article-title>
<source>Mol Cell Biol</source>
<year>1994</year>
<volume>14</volume>
<fpage>8212</fpage>
<lpage>8218</lpage>
<?supplied-pmid 7969158?><pub-id pub-id-type="pmid">7969158</pub-id></element-citation>
      </ref>
      <ref id="B55">
        <label>55</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Downey</surname><given-names>GP</given-names></name><name><surname>Butler</surname><given-names>JR</given-names></name><name><surname>Brumell</surname><given-names>J</given-names></name><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Kjeldsen</surname><given-names>L</given-names></name><name><surname>Sue</surname><given-names>A</given-names></name><name><surname>Quan</surname><given-names>AK</given-names></name><name><surname>Grinstein</surname><given-names>S</given-names></name></person-group>
<article-title>Chemotactic peptide-induced activation of MEK-2, the predominant isoform in human neutrophils. Inhibition by wortmannin</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>21005</fpage>
<lpage>21011</lpage>
<?supplied-pmid 8702863?><pub-id pub-id-type="pmid">8702863</pub-id></element-citation>
      </ref>
      <ref id="B56">
        <label>56</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winston</surname><given-names>BW</given-names></name><name><surname>Remigio</surname><given-names>LK</given-names></name><name><surname>Riches</surname><given-names>DW</given-names></name></person-group>
<article-title>Preferential involvement of MEK1 in the tumor necrosis factor-alphaâinduced activation of p42mapk/erk2 in mouse macrophages</article-title>
<source>J Biol Chem</source>
<year>1995</year>
<volume>270</volume>
<fpage>27391</fpage>
<lpage>27394</lpage>
<?supplied-pmid 7499190?><pub-id pub-id-type="pmid">7499190</pub-id></element-citation>
      </ref>
      <ref id="B57">
        <label>57</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Gomez</surname><given-names>N</given-names></name><name><surname>Moorhead</surname><given-names>G</given-names></name><name><surname>Lewis</surname><given-names>T</given-names></name><name><surname>Keyse</surname><given-names>SM</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group>
<article-title>Inactivation of p42 MAP kinase by protein phosphatase 2A and a protein tyrosine phosphatase, but not CL100, in various cell lines</article-title>
<source>Curr Biol</source>
<year>1995</year>
<volume>5</volume>
<fpage>283</fpage>
<lpage>295</lpage>
<?supplied-pmid 7780739?><pub-id pub-id-type="pmid">7780739</pub-id></element-citation>
      </ref>
      <ref id="B58">
        <label>58</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Robbins</surname><given-names>D</given-names></name><name><surname>Frost</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>A</given-names></name><name><surname>Lange</surname><given-names>CC</given-names></name><name><surname>Cobb</surname><given-names>MH</given-names></name></person-group>
<article-title>MEKK1 phosphorylates MEK1 and MEK2 but does not cause activation of mitogen-activated protein kinase</article-title>
<source>Proc Natl Acad Sci USA</source>
<year>1995</year>
<volume>92</volume>
<fpage>6808</fpage>
<lpage>6812</lpage>
<?supplied-pmid 7624324?><pub-id pub-id-type="pmid">7624324</pub-id></element-citation>
      </ref>
      <ref id="B59">
        <label>59</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bokemeyer</surname><given-names>D</given-names></name><name><surname>Sorokin</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>M</given-names></name><name><surname>Ahn</surname><given-names>NG</given-names></name><name><surname>Templeton</surname><given-names>DJ</given-names></name><name><surname>Dunn</surname><given-names>MJ</given-names></name></person-group>
<article-title>Induction of mitogen-activated protein kinase phosphatase 1 by the stress-activated protein kinase signaling pathway but not by extracellular signal-regulated kinase in fibroblasts</article-title>
<source>J Biol Chem</source>
<year>1996</year>
<volume>271</volume>
<fpage>639</fpage>
<lpage>642</lpage>
<?supplied-pmid 8557667?><pub-id pub-id-type="pmid">8557667</pub-id></element-citation>
      </ref>
      <ref id="B60">
        <label>60</label>
        <element-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Groom</surname><given-names>LA</given-names></name><name><surname>Sneddon</surname><given-names>AA</given-names></name><name><surname>Alessi</surname><given-names>DR</given-names></name><name><surname>Dowd</surname><given-names>S</given-names></name><name><surname>Keyse</surname><given-names>SM</given-names></name></person-group>
<article-title>Differential regulation of the MAP, SAP and RK/p38 kinases by Pyst1, a novel cytosolic dual-specificity phosphatase</article-title>
<source>EMBO (Eur Mol Biol Organ) J</source>
<year>1996</year>
<volume>15</volume>
<fpage>3621</fpage>
<lpage>3632</lpage>
<?supplied-pmid 8670865?><pub-id pub-id-type="pmid">8670865</pub-id></element-citation>
      </ref>
    </ref-list>
  </back>
  <floats-group>
    <fig id="F1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Transient expression of TRAF6-stimulated ERK activity in 293 cells. (<italic>A</italic>) Cells (10<sup>6</sup>) were transiently transfected with expression plasmid of TRAF proteins (5 Î¼g each) together with GST-ERK2. GST-ERK2 fusion protein was precipitated by use of glutathione Sepharose 4B from cell lysates 48 h after transfection and subjected to in vitro kinase assay using MBP as a substrate. <italic>Arrow</italic>, phosphorylated MBP in the autoradiogram. (<italic>B</italic>) Cells (10<sup>6</sup>) were transiently transfected with 100 ng of ERK-dependent activator pGAL4MycN and 500 ng of the reporter pGAL4tkLuc (<italic>a</italic>) or 20 ng of the NFÎºB-dependent luciferase reporter pkBtkLuc (<italic>b</italic>), together with empty vector, full-length TRAF6 (3 or 5 Î¼g), or the TRAF-C of TRAF6 (3 or 5 Î¼g). Total amount of DNA was adjusted with empty vector at 10 Î¼g. Luciferase activities were measured 48âh after transfection and normalized by Î²-gal expression. The extent of stimulation (relative activation) was calculated by comparison between luciferase activity given by the cells cotransfected with each TRAF expression plasmid and that of cells transfected with empty vector. (<italic>C</italic>) Cells (10<sup>6</sup>) were transiently cotransfected with either TRAF2, TRAF3, or TRAF5 (5 Î¼g each) and ERKâ (<italic>a</italic>) or NFÎºBâdependent luciferase reporter (<italic>b</italic>). Cell lysates were subjected to luciferase assay 48 h after transfection. The results shown in <italic>B</italic> and <italic>C</italic> were obtained from parallel experiments. For comparison, the extent of stimulation in ERK and NFÎºB by transient expression of TRAF6 (5 Î¼g) in <italic>B</italic> is also shown in <italic>C.</italic> The mean value of two independent experiments (<italic>column</italic>) was calculated from a mean value of a single experiment in triplicate (<italic>closed circles</italic>).</p>
      </caption>
      <graphic xlink:href="JEM.971654f1"/>
    </fig>
    <fig id="F4" position="float">
      <label>Figure 4</label>
      <caption>
        <p>ERK activation by cross-linking of full-length, but not that by CD40Î246, was prominently suppressed by dominant negative mutant of Ras. Cells (10<sup>6</sup>) were cotransfected with ERKâ (<italic>A</italic>) or NFÎºBâdependent reporter (<italic>B</italic>) and either 1 Î¼g of full-length CD40 (<italic>a</italic>) or CD40Î246 (<italic>b</italic>), together with 5 Î¼g of N17Ras, DNRaf, and MEK<sup>DN</sup>. Total amount of DNA was adjusted with empty vector at 10 Î¼g. Cells were stimulated with anti-CD40 mAb 24 h after transfection. After 24 h incubation, cell lysates were subjected to luciferase assay. Relative activation of ERK and NFÎºB in each transfection was calculated as described above. The mean value of two to three independent experiments (<italic>column</italic>) was calculated from a mean value of a single experiment in triplicate (<italic>closed circle</italic>).</p>
      </caption>
      <graphic xlink:href="JEM.971654f4"/>
    </fig>
    <fig id="F2" position="float">
      <label>Figure 2</label>
      <caption>
        <p>Inhibition of TRAF6-mediated ERK activity by dominant-negative mutant of Raf and MEK1, but not by Ras. Cells (10<sup>6</sup>) were cotransfected with ERK-dependent activator and reporter (<italic>A</italic>) or 500 ng of GST-ERK2 (<italic>B</italic>) and full-length TRAF6 (5 Î¼g), together with 5 Î¼g of N17Ras (<italic>DN Ras</italic>), DNRaf, or MEK1<sup>DN</sup> (<italic>DN MEK</italic>). Cell lysates were prepared 48 h after transfection and subjected to luciferase assay (<italic>A</italic>) or in vitro kinase assay (<italic>B</italic>). The mean value of relative activity of ERK- dependent luciferase reporter (<italic>column</italic>) in four independent experiments was calculated from a mean value of a single experiment in triplicate (<italic>closed circles</italic>). <italic>Arrowhead</italic>, phosphorylated MBP in the autoradiogram.</p>
      </caption>
      <graphic xlink:href="JEM.971654f2"/>
    </fig>
    <fig id="F3" position="float">
      <label>Figure 3</label>
      <caption>
        <p>Transient expression of TRAF-C of TRAF6 caused inhibition of ERK and NFÎºB activity mediated by cross-linking of CD40. Cells (10<sup>6</sup>) were transiently cotransfected with ERK-dependent activator and reporter (<italic>A</italic>), GST-ERK2 fusion construct (<italic>B</italic>), or NFÎºB-dependent reporter (<italic>C</italic>) and either l Î¼g of full-length CD40 (<italic>a</italic>) or CD40Î246 (<italic>b</italic>), together with 1, 3, or 5 Î¼g of TRAF-C domain of TRAF6. Total amount of DNA was adjusted with empty vector at 10 Î¼g. Cells were stimulated with anti-CD40 mAb 24 h after transfection. After 24 h of incubation, ERK activity was measured by luciferase assay (<italic>A</italic>) or in vitro kinase assay (<italic>B</italic>). <italic>Arrowhead</italic>, phosphorylated MBP in the autoradiogram is indicated by an arrowhead. NFÎºB activity was measured by luciferase assay (<italic>C</italic>). Relative activation of ERK and NFÎºB in 293 cells at each transfection was calculated as described above. The mean value of two independent experiments (<italic>column</italic>) was calculated from a mean value of a single experiment in triplicate (<italic>closed circles</italic>).</p>
      </caption>
      <graphic xlink:href="JEM.971654f3"/>
    </fig>
  </floats-group>
</article>

</metadata></record></GetRecord></OAI-PMH>